We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals, Inc.
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

105 hedge funds and large institutions have $264M invested in Tetraphase Pharmaceuticals, Inc. in 2015 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 33 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more call options, than puts

Call options by funds: $2.32M | Put options by funds: $1.78M

24% more capital invested

Capital invested by funds: $212M → $264M (+$51.7M)

0% more funds holding

Funds holding: 105105 (0)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 22

21% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 33

Holders
105
Holders Change
Holders Change %
0%
% of All Funds
2.75%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
22
Increased
26
Reduced
33
Closed
22
Calls
$2.32M
Puts
$1.78M
Net Calls
+$541K
Net Calls Change
+$1.8M
Name Holding Trade Value Shares
Change
Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$1.82M -$10.6K -53 -0.6%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$1.63M +$23.5K +118 +1%
USAA
28
United Services Automobile Association
Texas
$1.56M -$203K -1,016 -12%
EAM
29
Eventide Asset Management
Massachusetts
$1.4M -$346K -1,735 -20%
BIM
30
BlackRock Investment Management
Delaware
$1.21M +$7.98K +40 +0.7%
Deutsche Bank
31
Deutsche Bank
Germany
$1.19M +$587K +2,940 +98%
Charles Schwab
32
Charles Schwab
California
$1.1M -$226K -1,131 -17%
TA
33
Teachers Advisors
New York
$1.02M
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$861K +$488K +2,446 +132%
OAM
35
Oxford Asset Management
United Kingdom
$836K +$825K +4,133 New
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$776K -$2.77M -13,903 -78%
PI
37
Putnam Investments
Massachusetts
$752K
Two Sigma Advisers
38
Two Sigma Advisers
New York
$747K -$109K -545 -13%
CS
39
Credit Suisse
Switzerland
$741K +$288K +1,441 +64%
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$672K +$12K +60 +2%
DCC
41
Dow Chemical Company
Michigan
$652K
LCM
42
Landscape Capital Management
New Jersey
$640K +$636K +3,189 New
Macquarie Group
43
Macquarie Group
Australia
$629K -$81.8K -410 -12%
AllianceBernstein
44
AllianceBernstein
Tennessee
$503K -$29.9K -150 -6%
GF
45
Gabelli Funds
New York
$502K
Group One Trading
46
Group One Trading
Illinois
$476K +$474K +2,374 New
HCM
47
Highbridge Capital Management
New York
$466K +$464K +2,327 New
HT
48
HAP Trading
New York
$394K -$157K -786 -29%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$377K +$36.5K +183 +11%
Swiss National Bank
50
Swiss National Bank
Switzerland
$374K

TTPH Hedge Fund Activity: Q4 2015 in Review

105 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q4 2015, worth a combined $264M — up 24% from $212M a quarter earlier.

Fund positioning in TTPH was balanced in Q4 2015: 22 funds opened new positions, 22 closed out, 26 added to existing stakes and 33 trimmed.

The largest buyer was Canada Pension Plan Investment Board, opening a new position worth an estimated $19.7M. The largest seller was State Street, cutting an estimated $22.9M.

  • 105 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q4 2015, unchanged from Q3 2015.
  • Funds reported $264M of Tetraphase Pharmaceuticals, Inc. stock for Q4 2015, up 24% quarter-over-quarter.
  • 22 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q4 2015 and 22 closed out, a net change of 0 holders.
  • The largest Tetraphase Pharmaceuticals, Inc. buyer in Q4 2015 was Canada Pension Plan Investment Board, an estimated $19.7M added.
  • The largest Tetraphase Pharmaceuticals, Inc. seller in Q4 2015 was State Street, an estimated $22.9M sold.

Based on aggregated 13F filings for Q4 2015.